Related Experiment Video
Updated: May 25, 2026

A Three-Dimensional Digital Model for Early Diagnosis of Hepatic Fibrosis Based on Magnetic Resonance Elastography
Published on: July 21, 2023
A comparative study of non-invasive methods for fibrosis assessment in chronic HCV infection
Roxana Sirli1, Ioan Sporea, Simona Bota
1Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Timişoara, Romania. roxanasirli@gmail.com
Insights
Non-invasive tests for liver fibrosis in chronic hepatitis C virus (HCV) infection, including Transient Elastography (TE), show promise. TE demonstrated the best prediction for significant fibrosis and cirrhosis, though differences among methods were not always significant.
Area of Science:
- Hepatology
- Diagnostic Medicine
- Viral Hepatitis Research
Background:
- Chronic hepatitis C virus (HCV) infection can lead to liver fibrosis and cirrhosis.
- Accurate assessment of liver fibrosis is crucial for patient management.
- Non-invasive methods are increasingly explored as alternatives to liver biopsy.
Purpose of the Study:
- To compare the diagnostic accuracy of several non-invasive fibrosis assessment methods in chronic HCV patients.
- To evaluate platelet count, APRI, Forns, Lok, FIB-4 scores, and Transient Elastography (TE) against percutaneous liver biopsy (LB).
Main Methods:
- A study involving 150 chronic HCV patients.
- All patients underwent percutaneous liver biopsy (LB) and liver stiffness measurement (LSM) via TE in the same session.
- Biological tests for calculating APRI, Forns, Lok, and FIB-4 scores were performed concurrently.
Main Results:
- Transient Elastography (TE) showed the highest AUROC (0.773) for predicting significant fibrosis (Metavir F≥2), followed closely by APRI (0.763) and Forns (0.744).
- For predicting cirrhosis, TE (AUROC 0.979) was significantly superior to platelet count and FIB-4.
- All non-invasive tests demonstrated excellent negative predictive values (>97%) for excluding cirrhosis and significant correlations with fibrosis severity.
Conclusions:
- Liver stiffness measurement (LSM) via TE appears more sensitive for predicting significant fibrosis than other non-invasive scores, though not statistically significant.
- APRI and Forns scores demonstrated good performance in identifying significant fibrosis.
- LSM via TE is the optimal non-invasive method for predicting cirrhosis in chronic HCV patients.
Background And Aims:
To compare several non-invasive methods of fibrosis assessment in chronic hepatitis C virus (HCV) infection (platelet count, the APRI score, the Forns score, the Lok score, FIB-4, Transient Elastography [TE]), versus percutaneous liver biopsy (LB).
Methods:
Our study included 150 patients with chronic HCV infection in which LB, liver stiffness measurement (LSM) by means of TE and biological tests needed for calculating the scores (according to the classic formulas) were performed in the same session.
Results:
The best test for predicting significant fibrosis (F = 2 Metavir) was LSM with AUROC-0.773, followed by APRI (AUROC-0.763), Forns (AUROC-0.744), platelet count (AUROC-0.732), Lok (AUROC-0.701) and FIB-4 (AUROC-0.669), but the differences were not statistically significant (P > 0.05). For excluding cirrhosis, all the tests had excellent NPV (>97%). The best test for predicting cirrhosis was LSM (AUROC-0.979), significantly better than platelet count (AUROC- 0.899, P = 0.022) and than FIB-4 (AUROC-0.839, P = 0.042), otherwise the differences were not statistically significant (P > 0.05). All of the non-invasive tests were statistically significantly correlated (P < 0.0001) to the severity of fibrosis: APRI r=0.570; Forns r=0.540; Lok r=0.4843; FIB-4 r=0.4171; platelet count r=-0.4842.
Conclusions:
LSM by means of TE seems to be more sensitive than APRI, Forns, Lok and FIB-4 scores and than platelet count for the prediction of significant fibrosis, but the differences are not statistically significant. The APRI score and Forns scores correctly identified most (71%) of the patients having, or not having, significant fibrosis. LSM was the best method for predicting cirrhosis, but all the evaluated tests had excellent predictive value (AUROCs 0.839-0.979).
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
